Treatment of idiopathic thrombocytopenic purpura;Współczesne metody leczenia immunotrombocytopenii samoistnej

Acta Haematologica Polonica

Volumn 37, Issue SUPPL. 4, 2006, Pages 93-101

  Treliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Idiopathic thrombocytopenic purpura; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; RHESUS D ANTIBODY; RITUXIMAB;

CONFERENCE PAPER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; REMISSION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS;

EID: 33846971613     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346: 995-1008.
2. Huber MR, Kumar S, Tefferi A. Treatment advances in adult immune thrombocytopenic purpura. Ann Hematol. 2003; 82: 723-737.
3. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults.Br J Haematol. 2002; 118: 933-944.
4. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997; 126: 307-314.
5. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120: 574-596.
6. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005; 106: 2244-2251.
7. Portieljè JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97: 2549-2554.
8. Vianelli N, Valdre L, Fiacchini M et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica. 2001; 86: 504-509.
9. Cortelazzo S, Finazzi G, Buelli M et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991; 77: 31-33.
10. Bourgeois E, Caulier MT, Delarozee C et al. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol. 2003; 120: 1079-1088.
11. Cohen YC, Djulbegovic B, Shamai-Lubovitz O et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000; 160: 1630-1638.
12. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis.J Pediatr Hematol Oncol. 2003; 25: 660-664.
13. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88: 3-40.
14. Cheng Y, Wong RS, Soo YO et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003; 349: 831-836.
15. Borst F, Keuning JJ, van Hulsteijn H et al. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004; 83: 764-768.
16. Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol. 2006; 43 (Suppl 5): S3-10.
17. George JN, Raskob GE, Vesely SK et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003; 74: 161-169.
18. Schiavotto C, Ruggeri M, Rodeghiero F. Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura. Ann Hematol. 1995; 70: 89-90.
19. Newman GC, Novoa MV, Fodero EM et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001; 112: 1076-1078.
20. Scaradavou A, Woo B, Woloski BM et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997; 89: 2689-700.
21. Schwartz J, Leber MD, Gillis S et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol. 2003; 72: 94-98.
22. Kojouri K, Vesely SK, Terrell DR et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004; 104: 2623-2634.
23. Marcaccio MJ. Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. Semin Hematol. 2000; 37: 267-274.
24. Tsiotos G, Schlinkert RT. Laparoscopic splenectomy for immune thrombocytopenic purpura. Arch Surg. 1997; 132: 642-646.
25. Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995; 98: 436-442.
26. Caulier MT, Darloy F, Rose C et al. Splenic irradiation for chronic autoimmune thrombocytopenic purpura in patients with contra-indications to splenectomy. Br J Haematol. 1995; 91: 208-211.
27. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004; 104: 956-960.
28. Vesely SK, Perdue JJ, Rizvi MA et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004; 140: 112-120.
29. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost. 2006; 8: 1664-1672.
30. Robak T, Robak P. Treatment options or autoimmune cytopenias. Tranfus Med Hemother 2004; 31: 332-340.
31. Akoglu T, Paydas S, Bayik M et al. Megadose methylprednisolone pulse therapy in adult idiopathic thrombocytopenic purpura. Lancet. 1991; 337: 56.
32. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy.N Engl J Med. 1994; 330: 1560-1564.
33. Khouri I, Tuan B, Grant K. Immune thrombocytopenic purpura. N Engl J Med. 2002; 347: 449-450.
34. Wali YA, Al Lamki Z, Shah W et al. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 2002; 19: 329-335.
35. Warner M, Wasi P, Couban S et al. Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia. Am J Hematol. 1997; 54: 267-270.
36. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004; 125: 232-239.
37. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol. 2004; 72: 79-88.
38. George JN, Woodson RD, Kiss JE et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006; 21: 49-56.
39. Arnold DM, Dentali F, Meyer RM et al. Rituximab for treatment of adults with ITP: a asystematic review. Blood 2005; 106: 361a
40. Trelinski J, Chojnowski K, Kurenko-Deptuch M et al. Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease. Ann Hematol. 2005; 84: 835-836.
41. Bennett CM, Rogers ZR, Kinnamon Ddet al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006; 107: 2639-2642.
42. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995; 85: 351-358.
43. Quiquandon I, Fenaux P, Caulier MT et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990; 74: 223-228.
44. Emilia G, Morselli M, Luppi M et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002; 99: 1482-1485.
45. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001; 114: 121-125.
46. Hou M, Peng J, Shi Y et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003; 70: 353-357.
47. Newland A, Caulier MT, Schipperus MR et al. An opel-label, unit dose-finding study evaluating the safetyand platelet responseof a novel thrombopoietic protein (AMG531) in throbocytopenic Adult patients with immune thrombocytopenic purpura (ITP). Blood 2004; 104 (suppl 1, abstr 567)
48. Bussel JB, George JN, Kuter DJ et al. An open-label, dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG 531)in thrombocytopenic adult patients with immune thrombocytopenic purpura. Blood 2003; 102: 86a
49. Kuter DJ, Bussel JB, Aledort L et al. A phase 2 placebo controlled study evaluating the platelet count and safety of weekly dosing with a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with immune thrombocytopenic purpura. Blood 2004; 104: 148a-149a
50. Bussel JB, Kuter Dj, George JN et al. Long-term dosing of AMG 531 is effective and well tolerated in in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005; 106: 68a
51. Luengo JI, Duffy KJ, Shaw AN et al. Discovery of SB-497115, a small molecule thrombopoietin (TPO) receptor agonist fot the treatment of thrombocytopenia. Blood 2004; 104: 795a
52. GSK Announces Start Of Elttrombopag Phase III Worldwide Clinical Trial In Adults With Previously-Treated Idiopathic Thrombocytopenic Purpura.Medical News Today 2006. Available at: http://www.medicalnewstoday.com/medical-news.php? newsid=37752
53. Ballem PJ, Segal GM, Stratton JR et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.J Clin Invest. 1987; 80: 33-40.
54. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986; 80: 1051-1054.
55. Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol. 2003; 120: 909-910.